A large option trader is playing the upside in Amarin, thinking
that the drug developer has more gas in the tank.
AMRN surged 95 percent on April 18 after reporting that its AMR101
compound succeeded in reducing bad cholesterol. It's been holding
its ground since then and started to climb once again this week.
Today's option trade was a bullish call spread: A block of 4,000
June 22 calls was bought for $0.60 and an equal number of June 25
calls was sold for $0.20. That translates into a net cost of $0.40,
with the potential profit of 650 percent if AMRN closes at or above
$25 on expiration.
The shares are up 1.36 percent to $17.16 in afternoon trading.
Given the amount that AMRN has to appreciate in the next five weeks
for the calls to pay off, the investor apparently thinks that an
explosive move is possible but does not want the risk of owning
shares, which also have the potential to fall.
Using options is a good solution in such a situation because they
provide upside exposure at much lower cost than owning stock. (See
our Education section)
The next big news event for AMRN could be the announcement of a
partnership with a larger company to market AMR101. It isn't
expected to get regulatory approval until early next year.
Calls outnumber puts by almost 4 to 1 in the stock so far
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.